AI Simulations Predict Drug Synergies the FDA Won’t Test (2026)
Introduction: The Problem with Conventional Trials The FDA and mainstream oncology focus almost exclusively on genetic-targeted therapies and single-drug clinical trials. While this approach has yielded breakthroughs in some cancers, it misses a critical opportunity : the synergistic effects of drug combinations targeting tumor metabolism . Standard RCTs are expensive, slow, and designed to satisfy regulatory requirements, not explore every scientifically plausible drug synergy. Millions of combinations of repurposed drugs, dietary interventions, and metabolic modulators will never be formally tested . Enter AI-driven simulations: a cost-effective, high-throughput method to predict which combinations may be most effective — before a single patient trial begins. 1. How AI Simulations Work in Cancer Therapy Modern AI models integrate: Tumor metabolic pathways — Warburg effect, mitochondrial dysfunction, nutrient dependencies Drug mechanisms — Metformin, fenbendazole, ivermectin, methy...